96 related articles for article (PubMed ID: 18988489)
1. [Acyclic nucleoside phosphonates as potential antineoplastic agents].
Votruba I; Otová B; Holý A
Cas Lek Cesk; 2008; 147(9):471-7. PubMed ID: 18988489
[TBL] [Abstract][Full Text] [Related]
2. GS-9219--a novel acyclic nucleotide analogue with potent antineoplastic activity in dogs with spontaneous non-Hodgkin's lymphoma.
Reiser H; Wang J; Chong L; Watkins WJ; Ray AS; Shibata R; Birkus G; Cihlar T; Wu S; Li B; Liu X; Henne IN; Wolfgang GH; Desai M; Rhodes GR; Fridland A; Lee WA; Plunkett W; Vail D; Thamm DH; Jeraj R; Tumas DB
Clin Cancer Res; 2008 May; 14(9):2824-32. PubMed ID: 18451250
[TBL] [Abstract][Full Text] [Related]
3. Assessment of GS-9219 in a pet dog model of non-Hodgkin's lymphoma.
Vail DM; Thamm DH; Reiser H; Ray AS; Wolfgang GH; Watkins WJ; Babusis D; Henne IN; Hawkins MJ; Kurzman ID; Jeraj R; Vanderhoek M; Plaza S; Anderson C; Wessel MA; Robat C; Lawrence J; Tumas DB
Clin Cancer Res; 2009 May; 15(10):3503-10. PubMed ID: 19417014
[TBL] [Abstract][Full Text] [Related]
4. Antiproliferative effects of octadecyloxyethyl 9-[2-(phosphonomethoxy)ethyl]guanine against Me-180 human cervical cancer cells in vitro and in vivo.
Valiaeva N; Trahan J; Aldern KA; Beadle JR; Hostetler KY
Chemotherapy; 2010; 56(1):54-9. PubMed ID: 20215748
[TBL] [Abstract][Full Text] [Related]
5. N6-cyclopropyl-PMEDAP: a novel derivative of 9-(2-phosphonylmethoxyethyl)-2,6-diaminopurine (PMEDAP) with distinct metabolic, antiproliferative, and differentiation-inducing properties.
Hatse S; Naesens L; De Clercq E; Balzarini J
Biochem Pharmacol; 1999 Jul; 58(2):311-23. PubMed ID: 10423173
[TBL] [Abstract][Full Text] [Related]
6. Intracellular metabolism and action of acyclic nucleoside phosphonates on DNA replication.
Pisarev VM; Lee SH; Connelly MC; Fridland A
Mol Pharmacol; 1997 Jul; 52(1):63-8. PubMed ID: 9224813
[TBL] [Abstract][Full Text] [Related]
7. In vivo modulation of angiogenic gene expression by acyclic nucleoside phosphonates PMEDAP and PMEG.
Otová B; Hrdy J; Votruba I; Holy A
Anticancer Res; 2009 Apr; 29(4):1295-302. PubMed ID: 19414378
[TBL] [Abstract][Full Text] [Related]
8. Antiretroviral activities of acyclic nucleoside phosphonates [9-(2-phosphonylmethoxyethyl)adenine, 9-(2-phosphonylmethoxyethyl)guanine, (R)-9-(2-phosphonylmethoxypropyl)adenine, and MDL 74,968] in cell cultures and murine sarcoma virus-infected newborn NMRI mice.
Balzarini J; Vahlenkamp T; Egberink H; Hartmann K; Witvrouw M; Pannecouque C; Casara P; Navé JF; De Clercq E
Antimicrob Agents Chemother; 1997 Mar; 41(3):611-6. PubMed ID: 9056002
[TBL] [Abstract][Full Text] [Related]
9. Novel acyclic nucleotide analogues GS-343074 and GS-424044 demonstrate antiproliferative and pro-apoptotic activity in canine neoplastic cell lines.
Lawrence JA; Huelsmeyer MK; Thamm DH; Tumas DB; Birkus G; Kurzman I; Vail DM
Vet Comp Oncol; 2015 Sep; 13(3):246-54. PubMed ID: 23672437
[TBL] [Abstract][Full Text] [Related]
10. Tanovea® for the treatment of lymphoma in dogs.
De Clercq E
Biochem Pharmacol; 2018 Aug; 154():265-269. PubMed ID: 29778492
[TBL] [Abstract][Full Text] [Related]
11. GS-9219/VDC-1101--a prodrug of the acyclic nucleotide PMEG has antitumor activity in spontaneous canine multiple myeloma.
Thamm DH; Vail DM; Kurzman ID; Babusis D; Ray AS; Sousa-Powers N; Tumas DB
BMC Vet Res; 2014 Jan; 10():30. PubMed ID: 24460928
[TBL] [Abstract][Full Text] [Related]
12. The Holý Trinity: the acyclic nucleoside phosphonates.
De Clercq E
Adv Pharmacol; 2013; 67():293-316. PubMed ID: 23886004
[TBL] [Abstract][Full Text] [Related]
13. 9-(2-phosphonylmethoxyethyl)-N6-cyclopropyl-2,6-diaminopurine: a novel prodrug of 9-(2-phosphonylmethoxyethyl)guanine with improved antitumor efficacy and selectivity in choriocarcinoma-bearing rats.
Naesens L; Hatse S; Segers C; Verbeken E; De Clercq E; Waer M; Balzarini J
Oncol Res; 1999; 11(4):195-203. PubMed ID: 10566618
[TBL] [Abstract][Full Text] [Related]
14. [The efficacy of nucleoside/nucleotide analogue on chronic hepatitis B].
Lin Q; Zhang DZ
Zhonghua Gan Zang Bing Za Zhi; 2009 Oct; 17(10):722-5. PubMed ID: 19874684
[No Abstract] [Full Text] [Related]
15. Involvement of MAP kinases in the cytotoxicity of acyclic nucleoside phosphonates.
Mertlíková-Kaiserová H; Nejedlá M; Holy A; Votruba I
Anticancer Res; 2012 Feb; 32(2):497-501. PubMed ID: 22287737
[TBL] [Abstract][Full Text] [Related]
16. Cytostatic activity of antiviral acyclic nucleoside phosphonates in rodent lymphocytes.
Zídek Z; Potmesil P; Holý A
Toxicol Appl Pharmacol; 2003 Nov; 192(3):246-53. PubMed ID: 14575642
[TBL] [Abstract][Full Text] [Related]
17. Distinct modulation of telomere length in two T-lymphoblastic leukemia cell lines by cytotoxic nucleoside phosphonates PMEG and PMEDAP.
Hájek M; Cvilink V; Votruba I; Holý A; Mertlíková-Kaiserová H
Eur J Pharmacol; 2010 Sep; 643(1):6-12. PubMed ID: 20599933
[TBL] [Abstract][Full Text] [Related]
18. 9-(2-Phosphonylmethoxyethyl)-N6-cyclopropyl-2,6-diaminopurine (cpr-PMEDAP) as a prodrug of 9-(2-phosphonylmethoxyethyl)guanine (PMEG).
Compton ML; Toole JJ; Paborsky LR
Biochem Pharmacol; 1999 Aug; 58(4):709-14. PubMed ID: 10413310
[TBL] [Abstract][Full Text] [Related]
19. Mutations in adenosine deaminase-like (ADAL) protein confer resistance to the antiproliferative agents N6-cyclopropyl-PMEDAP and GS-9219.
Frey CR; Andrei G; Votruba I; Cannizzaro C; Han B; Fung W; Hung M; Liu X; Geleziunas R; Fiten P; Opdenakker G; Snoeck R; Cihlar T
Anticancer Res; 2013 May; 33(5):1899-912. PubMed ID: 23645737
[TBL] [Abstract][Full Text] [Related]
20. Point mutations in human guanylate kinase account for acquired resistance to anticancer nucleotide analogue PMEG.
Mertlíková-Kaiserová H; Rumlová M; Tloušťová E; Procházková E; Holý A; Votruba I
Biochem Pharmacol; 2011 Jul; 82(2):131-8. PubMed ID: 21515241
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
